Effect of Miglitol (Bay m1099), a new alpha-glucosidase inhibitor, on glucose, insulin, C-peptide and GIP responses to an oral sucrose load in patients with post-prandial hypoglycaemic symptoms.

Renard, E; Parer-Richard, C; Richard, J L; Jureidini, S; Orsetti, A; Mirouze, J

Renard, E; Parer-Richard, C; Richard, J L; Jureidini, S; Orsetti, A; Mirouze, J.

Affiliation

Renard E; Clinique des Maladies métaboliques et endocriniennes, Hôpital Lapeyronie, Montpellier, France.

Diabete Metab ; 17(3): 355-62, 1991.

Article in En | MEDLINE | ID: mdl-1884880

Subject(s)

Blood Glucose/metabolism; C-Peptide/blood; Gastric Inhibitory Polypeptide/blood; Glucosamine/analogs & derivatives; Glycoside Hydrolase Inhibitors; Hypoglycemia/blood; Insulin/blood; Sucrose/pharmacology; 1-Deoxynojirimycin/analogs & derivatives; Administration, Oral; Double-Blind Method; Female; Glucosamine/pharmacology; Glucose Tolerance Test; Humans; Imino Pyranoses; Male; Middle Aged; Sucrose/administration & dosage

Search on Google

Add to My VHL

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Sucrose / Blood Glucose / C-Peptide / Gastric Inhibitory Polypeptide / Glycoside Hydrolase Inhibitors / Glucosamine / Hypoglycemia / Insulin Type of study: Clinical_trials / Diagnostic_studies Limits: Female / Humans / Male / Middle aged Language: En Journal: Diabete Metab Year: 1991 Document type: Article Affiliation country: France Country of publication: France

Search on Google

Add to My VHL

XML

PubMed Links